{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T05:15:57Z","timestamp":1777439757514,"version":"3.51.4"},"reference-count":157,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T00:00:00Z","timestamp":1663632000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Pet Trust Grant","award":["#054059"],"award-info":[{"award-number":["#054059"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Osteosarcoma (OS) is the most common type of bone cancer, with ~30% of patients developing secondary\/metastatic tumors. The molecular complexity of tumor metastasis and the lack of effective therapies for OS has cultivated interest in exploiting the proteasome as a molecular target for anti-cancer therapy. As our understanding towards the behavior of malignant cells expands, it is evident that cancerous cells display a greater reliance on the proteasome to maintain homeostasis and sustain efficient biological activities. This led to the development and approval of first- and second-generation proteasome inhibitors (PIs), which have improved outcomes for patients with multiple myeloma and mantle cell lymphoma. Researchers have since postulated the therapeutic potential of PIs for the treatment of OS. As such, this review aims to summarize the biological effects and latest findings from clinical trials investigating PI-based treatments for OS. Integrating PIs into current treatment regimens may better outcomes for patients diagnosed with OS.<\/jats:p>","DOI":"10.3390\/cancers14194544","type":"journal-article","created":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T21:12:53Z","timestamp":1663708373000},"page":"4544","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Proteasome Inhibitors and Their Potential Applicability in Osteosarcoma Treatment"],"prefix":"10.3390","volume":"14","author":[{"given":"Cassidy M.","family":"Van Stiphout","sequence":"first","affiliation":[{"name":"Department of Biomedical Sciences, Ontario Veterinary College, University of Guelph, Guelph, ON N1G 2W1, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anita K.","family":"Luu","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Ontario Veterinary College, University of Guelph, Guelph, ON N1G 2W1, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alicia M.","family":"Viloria-Petit","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Ontario Veterinary College, University of Guelph, Guelph, ON N1G 2W1, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,9,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1634\/theoncologist.9-4-422","article-title":"Biology and Therapeutic Advances for Pediatric Osteosarcoma","volume":"9","author":"Marina","year":"2004","journal-title":"Oncologist"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.1200\/JCO.2014.59.4895","article-title":"Osteosarcoma: Current Treatment and a Collaborative Pathway to Success","volume":"33","author":"Isakoff","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"103126","DOI":"10.1016\/j.critrevonc.2020.103126","article-title":"Osteosarcoma of the Jaws: An Overview of the Pathophysiological Mechanisms | Elsevier Enhanced Reader","volume":"156","author":"Bertin","year":"2020","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s12938-021-00860-0","article-title":"Osteosarcoma: A Review of Current and Future Therapeutic Approaches","volume":"20","author":"Zhao","year":"2021","journal-title":"BioMed. Eng. OnLine"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Marchandet, L., Lallier, M., Charrier, C., Baud\u2019huin, M., Ory, B., and Lamoureux, F. (2021). Mechanisms of Resistance to Conventional Therapies for Osteosarcoma. Cancers, 13.","DOI":"10.3390\/cancers13040683"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"\u00d6zt\u00fcrk, R. (2021). Current Therapeutic Approaches for Osteosarcoma. Recent Adv. Bone Tumours Osteoarthr.","DOI":"10.5772\/intechopen.98434"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1080\/14656566.2021.1936499","article-title":"State-of-the-art, approved therapeutics for the pharmacological management of osteosarcoma","volume":"22","author":"Meazza","year":"2021","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"16991","DOI":"10.1038\/srep16991","article-title":"Identification of Synergistic, Clinically Achievable, Combination Therapies for Osteosarcoma","volume":"5","author":"Yu","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.coph.2014.02.002","article-title":"Recent advances in osteosarcoma","volume":"16","author":"Botter","year":"2014","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/dna.2006.0505","article-title":"Molecular Pathogenesis of Osteosarcoma","volume":"26","author":"Kansara","year":"2007","journal-title":"DNA Cell. Biol."},{"key":"ref_11","unstructured":"Franceschini, N., and Cleton-Jansen, A.-M. (2021, September 12). Bov\u00e9e Judith VMG Bone: Osteosarcoma. Available online: http:\/\/atlasgeneticsoncology.org\/Tumors\/ConvOsteoID5344.html."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"vii320","DOI":"10.1093\/annonc\/mdq276","article-title":"Osteosarcoma","volume":"21","author":"Ritter","year":"2010","journal-title":"Ann. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"115070","DOI":"10.1016\/j.bone.2019.115070","article-title":"Common Genetic Variation and Risk of Osteosarcoma in a Multi-Ethnic Pediatric and Adolescent Population","volume":"130","author":"Zhang","year":"2020","journal-title":"Bone"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s40744-016-0050-2","article-title":"Osteosarcoma Overview","volume":"4","author":"Lindsey","year":"2016","journal-title":"Rheumatol. Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1177\/014556131309200704","article-title":"Osteosarcoma","volume":"92","author":"Thompson","year":"2013","journal-title":"Ear Nose Throat J."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/bjc.1975.136","article-title":"The metastatic patterns of osteosarcoma","volume":"32","author":"Jeffree","year":"1975","journal-title":"Br. J. Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1200\/JCO.2003.03.141","article-title":"Postrelapse Survival in Osteosarcoma of the Extremities: Prognostic Factors for Long-Term Survival","volume":"21","author":"Ferrari","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/978-3-319-07323-1_4","article-title":"Osteosarcoma","volume":"162","author":"Moore","year":"2014","journal-title":"Cancer Treat. Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1200\/JCO.1994.12.9.1849","article-title":"Pulmonary Metastases of Stage IIB Extremity Osteosarcoma and Subsequent Pulmonary Metastases","volume":"12","author":"Ward","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0899-7071(03)00206-7","article-title":"Imaging Findings of Extrapulmonary Metastases of Osteosarcoma","volume":"28","author":"Kim","year":"2004","journal-title":"Clin. Imaging"},{"key":"ref_21","first-page":"99","article-title":"The Metastasectomy and Timing of Pulmonary Metastases on the Outcome of Osteosarcoma Patients","volume":"3","author":"Huang","year":"2009","journal-title":"Clin. Med. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1051\/sicotj\/2017028","article-title":"Osteosarcoma: A Comprehensive Review","volume":"4","author":"Misaghi","year":"2018","journal-title":"SICOT J."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1177\/15353702211067718","article-title":"Innovative Approaches for Treatment of Osteosarcoma","volume":"247","author":"Rothzerg","year":"2022","journal-title":"Exp. Biol. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1159\/000456598","article-title":"A New Perspective for Osteosarcoma Therapy: Proteasome Inhibition by MLN9708\/2238 Successfully Induces Apoptosis and Cell Cycle Arrest and Attenuates the Invasion Ability of Osteosarcoma Cells in Vitro","volume":"41","author":"Liu","year":"2017","journal-title":"Cell. Physiol. Biochem."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"5967","DOI":"10.7314\/APJCP.2014.15.15.5967","article-title":"Review of the Molecular Pathogenesis of Osteosarcoma","volume":"15","author":"He","year":"2014","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1053\/j.seminoncol.2018.01.004","article-title":"Proteasome Inhibitors: Structure and Function","volume":"44","author":"Nunes","year":"2017","journal-title":"Semin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Adams, J. (2004). Proteasome Inhibitors in Cancer Therapy. Cancer Chemoprev., 635\u2013642.","DOI":"10.1007\/978-1-59259-767-3_41"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e00894","DOI":"10.1016\/j.heliyon.2018.e00894","article-title":"Biological Consequences of Structural and Functional Proteasome Diversity","volume":"4","author":"Morozov","year":"2018","journal-title":"Heliyon"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.freeradbiomed.2011.03.031","article-title":"Ubiquitin-Proteasome Pathway and Cellular Responses to Oxidative Stress","volume":"51","author":"Shang","year":"2011","journal-title":"Free Radic. Biol. Med."},{"key":"ref_30","first-page":"726","article-title":"The Ubiquitin Proteasome Pathway (UPP) in the Regulation of Cell Cycle Control and DNA Damage Repair and Its Implication in Tumorigenesis","volume":"5","author":"Tu","year":"2012","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/med.1009","article-title":"The Ubiquitin-Proteasome Pathway and Proteasome Inhibitors","volume":"21","author":"Myung","year":"2001","journal-title":"Med. Res. Rev."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1681\/ASN.2006010083","article-title":"Protein Degradation by the Ubiquitin\u2013Proteasome Pathway in Normal and Disease States","volume":"17","author":"Lecker","year":"2006","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_33","first-page":"e0174","article-title":"The Ubiquitination Machinery of the Ubiquitin System","volume":"12","author":"Callis","year":"2014","journal-title":"Arab. Book Am. Soc. Plant Biol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1146\/annurev-biophys-051013-022958","article-title":"Structural and Functional Insights to Ubiquitin-Like Protein Conjugation","volume":"43","author":"Streich","year":"2014","journal-title":"Annu. Rev. Biophys."},{"key":"ref_35","first-page":"423","article-title":"E2 Enzymes: More than Just Middle Men","volume":"26","author":"Stewart","year":"2016","journal-title":"Nat. Publ. Group"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Ito, S. (2020). Proteasome Inhibitors for the Treatment of Multiple Myeloma. Cancers, 12.","DOI":"10.3390\/cancers12020265"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.cell.2007.05.007","article-title":"Proteasomes: Machines for All Reasons","volume":"129","author":"DeMartino","year":"2007","journal-title":"Cell"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"289","DOI":"10.4161\/cc.4.2.1414","article-title":"Proteasome Inhibition in the Treatment of Cancer","volume":"4","author":"Richardson","year":"2005","journal-title":"Cell Cycle"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1098\/rstb.1999.0494","article-title":"The Proteasome: A Macromolecular Assembly Designed for Controlled Proteolysis","volume":"354","author":"Zwickl","year":"1999","journal-title":"Philos. Trans. R. Soc. B Biol. Sci."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s12079-011-0121-7","article-title":"Proteasome Inhibitors in Cancer Therapy","volume":"5","author":"Crawford","year":"2011","journal-title":"J. Cell Commun. Signal."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nrclinonc.2016.206","article-title":"Proteasome Inhibitors in Cancer Therapy","volume":"14","author":"Manasanch","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1743-7563.2012.01535.x","article-title":"MG132, a proteasome inhibitor, induces apoptosis in tumor cells","volume":"9","author":"Guo","year":"2013","journal-title":"Asia Pac. J. Clin. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s10555-017-9707-8","article-title":"The Proteasome and Proteasome Inhibitors in Multiple Myeloma","volume":"36","author":"Gandolfi","year":"2017","journal-title":"Cancer Metastasis Rev."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"277","DOI":"10.4143\/crt.2021.320","article-title":"Enrichment of Wee1\/CDC2 and NF-\u039aB Signaling Pathway Constituents Mutually Contributes to CDDP Resistance in Human Osteosarcoma","volume":"54","author":"Hu","year":"2022","journal-title":"Cancer Res. Treat."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1111\/vco.12413","article-title":"Pre-Clinical Evaluation of Proteasome Inhibitors for Canine and Human Osteosarcoma","volume":"16","author":"Patatsos","year":"2018","journal-title":"Vet. Comp. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/1878-0261.12176","article-title":"Activation of TNF-a\/NF-JB Axis Enhances CRL4B DCAF11 E3 Ligase Activity and Regulates Cell Cycle Progression in Human Osteosarcoma Cells","volume":"12","author":"Zhang","year":"2018","journal-title":"Mol. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1177\/0300060513490618","article-title":"Bortezomib Induces Apoptosis and Autophagy in Osteosarcoma Cells through Mitogen-Activated Protein Kinase Pathway in Vitro","volume":"41","author":"Lou","year":"2013","journal-title":"J. Int. Med. Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"465","DOI":"10.3109\/10799893.2015.1122045","article-title":"JNK Pathway in Osteosarcoma: Pathogenesis and Therapeutics","volume":"36","author":"Li","year":"2015","journal-title":"J. Recept. Signal Transduct."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1038\/sj.cdd.4401251","article-title":"Induction of Apoptosis in Human Osteosarcoma Saos-2 Cells by the Proteasome Inhibitor MG132 and the Protective Effect of PRb","volume":"10","author":"Lauricella","year":"2003","journal-title":"Cell Death Differ."},{"key":"ref_50","first-page":"6725","article-title":"Prognostic Value of P53 Alterations in Human Osteosarcoma: A Meta Analysis","volume":"7","author":"Yao","year":"2014","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Synoradzki, K.J., Bartnik, E., Czarnecka, A.M., Fiedorowicz, M., Firlej, W., Brodziak, A., Stasinska, A., Rutkowski, P., and Grieb, P. (2021). Tp53 in Biology and Treatment of Osteosarcoma. Cancers, 13.","DOI":"10.3390\/cancers13174284"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1002\/ijc.31389","article-title":"Genetic and Clonal Dissection of Osteosarcoma Progression and Lung Metastasis","volume":"143","author":"Xu","year":"2018","journal-title":"Int. J. Cancer"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"12893","DOI":"10.1074\/jbc.272.20.12893","article-title":"P53-Dependent Induction of Apoptosis by Proteasome Inhibitors","volume":"272","author":"Lopes","year":"1997","journal-title":"J. Biol. Chem."},{"key":"ref_54","first-page":"239","article-title":"Role of P53 in Cell Cycle Regulation and Apoptosis Following Exposure to Proteasome Inhibitors","volume":"11","author":"Chen","year":"2000","journal-title":"Cell Growth Differ."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.ajpath.2010.11.010","article-title":"Proteasome Inhibitors Induce P53-Independent Apoptosis in Human Cancer Cells","volume":"178","author":"Pandit","year":"2011","journal-title":"Am. J. Pathol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1002\/ijc.32976","article-title":"Proteasome Inhibitors and Smac Mimetics Cooperate to Induce Cell Death in Diffuse Large B-Cell Lymphoma by Stabilizing NOXA and Triggering Mitochondrial Apoptosis","volume":"147","author":"Dietz","year":"2020","journal-title":"Int. J. Cancer"},{"key":"ref_57","first-page":"2803","article-title":"Non-Covalent Proteasome Inhibitor PI-1840 Induces Apoptosis and Autophagy in Osteosarcoma Cells","volume":"41","author":"Chen","year":"2019","journal-title":"Oncol. Rep."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"655","DOI":"10.3727\/096504017X15119525209765","article-title":"Proteasome Inhibitor MG132 Enhances Cisplatin-Induced Apoptosis in Osteosarcoma Cells and Inhibits Tumor Growth","volume":"26","author":"Sun","year":"2018","journal-title":"Oncol. Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"11906","DOI":"10.1074\/jbc.M113.533950","article-title":"Discovery of PI-1840, a Novel Noncovalent and Rapidly Reversible Proteasome Inhibitor with Anti-Tumor Activity","volume":"289","author":"Kazi","year":"2014","journal-title":"J. Biol. Chem."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1007\/s10495-006-8048-9","article-title":"The TRAIL Apoptotic Pathway Mediates Proteasome Inhibitor Induced Apoptosis in Primary Chronic Lymphocytic Leukemia Cells","volume":"11","author":"Kabore","year":"2006","journal-title":"Apoptosis"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.bbrc.2013.08.066","article-title":"Proteasome Inhibitor MG132 Enhances TRAIL-Induced Apoptosis and Inhibits Invasion of Human Osteosarcoma OS732 Cells","volume":"439","author":"Li","year":"2013","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s10555-017-9697-6","article-title":"Proteasome-Associated Deubiquitinases and Cancer","volume":"36","author":"Mofers","year":"2017","journal-title":"Cancer Metastasis Rev."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Deshaies, R.J. (2014). Proteotoxic Crisis, the Ubiquitin-Proteasome System, and Cancer Therapy. BMC Biol., 12.","DOI":"10.1186\/s12915-014-0094-0"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"6129","DOI":"10.1158\/1078-0432.CCR-16-0326","article-title":"MTOR Inhibition Mitigates Enhanced MRNA Translation Associated with the Metastatic Phenotype of Osteosarcoma Cells In Vivo","volume":"22","author":"Morrow","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Guang, M.H.Z., Kavanagh, E., Dunne, L., Dowling, P., Zhang, L., Lindsay, S., Bazou, D., Goh, C., Hanley, C., and Bianchi, G. (2019). Targeting Proteotoxic Stress in Cancer: A Review of the Role That Protein Quality Control Pathways Play in Oncogenesis. Cancers, 11.","DOI":"10.3390\/cancers11010066"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"114737","DOI":"10.1016\/j.bcp.2021.114737","article-title":"The Unfolded Protein Response as Regulator of Cancer Stemness and Differentiation: Mechanisms and Implications for Cancer Therapy","volume":"192","author":"Liang","year":"2021","journal-title":"Biochem. Pharmacol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1016\/j.celrep.2015.05.043","article-title":"Structural and Functional Analysis of the GADD34:PP1 EIF2\u03b1 Phosphatase","volume":"11","author":"Choy","year":"2015","journal-title":"Cell Rep."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1126\/science.1209038","article-title":"The Unfolded Protein Response: From Stress Pathway to Homeostatic Regulation","volume":"334","author":"Walter","year":"2011","journal-title":"Science"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"4907","DOI":"10.1182\/blood-2005-08-3531","article-title":"Proteasome Inhibitors Induce a Terminal Unfolded Protein Response in Multiple Myeloma Cells","volume":"107","author":"Obeng","year":"2006","journal-title":"Blood"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1158\/1078-0432.CCR-07-2218","article-title":"Proteasome Inhibitors in Cancer Therapy: Lessons from the First Decade","volume":"14","author":"Orlowski","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1146\/annurev.pharmtox.46.120604.141300","article-title":"The Proteasome and Proteasome Inhibitors in Cancer Therapy","volume":"46","author":"PM","year":"2006","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1517\/13543784.17.6.879","article-title":"The Potential of Proteasome Inhibitors in Cancer Therapy","volume":"17","author":"Sterz","year":"2008","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1111\/jcmm.12279","article-title":"Proteasome Inhibitors-Molecular Basis and Current Perspectives in Multiple Myeloma","volume":"18","author":"Kubiczkova","year":"2014","journal-title":"J. Cell. Mol. Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"6282","DOI":"10.1158\/0008-5472.CAN-05-0676","article-title":"Proteasome Inhibitors Trigger NOXA-Mediated Apoptosis in Melanoma and Myeloma Cells","volume":"65","author":"Qin","year":"2005","journal-title":"Cancer Res."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.molmed.2011.02.004","article-title":"Dog Models of Naturally Occurring Cancer","volume":"17","author":"Rowell","year":"2011","journal-title":"Trends Mol. Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1177\/03009858221083038","article-title":"Canine and Murine Models of Osteosarcoma","volume":"59","author":"Beck","year":"2022","journal-title":"Vet. Pathol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s13028-017-0341-9","article-title":"Comparative Review of Human and Canine Osteosarcoma: Morphology, Epidemiology, Prognosis, Treatment and Genetics","volume":"59","author":"Simpson","year":"2017","journal-title":"Acta Vet. Scand."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1093\/ilar\/ilu009","article-title":"Canine Osteosarcoma: A Naturally Occurring Disease to Inform Pediatric Oncology","volume":"55","author":"Fenger","year":"2014","journal-title":"ILAR J."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Paoloni, M., Davis, S., Lana, S., Withrow, S., Sangiorgi, L., Picci, P., Hewitt, S.M., Triche, T., Meltzer, P., and Khanna, C. (2009). Canine Tumor Cross-Species Genomics Uncovers Targets Linked to Osteosarcoma Progression. BMC Genom., 10.","DOI":"10.1186\/1471-2164-10-625"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/s41568-020-0297-3","article-title":"Improving Human Cancer Therapy through the Evaluation of Pet Dogs","volume":"20","author":"LeBlanc","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"859","DOI":"10.2165\/00003495-200969070-00006","article-title":"Bortezomib","volume":"69","author":"Curran","year":"2012","journal-title":"Drugs"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/ijc.25024","article-title":"Proteasome Inhibition with Bortezomib Suppresses Growth and Induces Apoptosis in Osteosarcoma","volume":"127","author":"Shapovalov","year":"2010","journal-title":"Int. J. Cancer"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/cncr.20968","article-title":"A Multicenter Phase II Study of Bortezomib in Recurrent or Metastatic Sarcomas","volume":"103","author":"Maki","year":"2005","journal-title":"Cancer"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1002\/ijc.30792","article-title":"Bortezomib Sensitizes Human Osteosarcoma Cells to Adriamycin-Induced Apoptosis through ROS-Dependent Activation of p-EIF2\u03b1\/ATF4\/CHOP Axis","volume":"141","author":"Xian","year":"2017","journal-title":"Int. J. Cancer"},{"key":"ref_85","unstructured":"(2021, September 12). Bortezomib in Treating Patients with Advanced or Metastatic Sarcoma-Full Text View-ClinicalTrials.Gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00027716?term=osteosarcoma&cond=bortezomib&draw=2&rank=1."},{"key":"ref_86","unstructured":"(2021, September 12). Bortezomib and Gemcitabine in Treating Older Patients with Advanced Solid Tumors-Full Text View-ClinicalTrials.Gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00620295?term=osteosarcoma&cond=bortezomib&draw=2&rank=2."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.trsl.2018.03.002","article-title":"Next-Generation Proteasome Inhibitors for Cancer Therapy","volume":"198","author":"Park","year":"2018","journal-title":"Transl. Res."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Somarelli, J.A., Rupprecht, G., Altunel, E., Flamant, E.M., Rao, S., Sivaraj, D., Lazarides, A.L., Hoskinson, S.M., Sheth, M.U., and Cheng, S. (2020). A Comparative Oncology Drug Discovery Pipeline to Identify and Validate New Treatments for Osteosarcoma. Cancers, 12.","DOI":"10.1101\/2020.10.19.346387"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1002\/ijc.33046","article-title":"Histone Deacetylase Inhibition Prevents the Growth of Primary and Metastatic Osteosarcoma","volume":"147","author":"McGuire","year":"2020","journal-title":"Int. J. Cancer"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s40164-017-0086-1","article-title":"Pharmacokinetics of Carfilzomib in Patients with Advanced Malignancies and Varying Degrees of Hepatic Impairment: An Open-Label, Single-Arm, Phase 1 Study","volume":"6","author":"Brown","year":"2017","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"804","DOI":"10.2174\/1568009621666210504085527","article-title":"Cytotoxicity and Target Modulation in Pediatric Solid Tumors by the Proteasome Inhibitor Carfilzomib","volume":"21","author":"Thakur","year":"2021","journal-title":"Curr. Cancer Drug Targets"},{"key":"ref_92","unstructured":"(2021, September 20). Extended Infusion Carfilzomib on a Weekly Schedule in Patients with Advanced Solid Tumors-Full Text View-ClinicalTrials.Gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02257476?term=solid+tumors&cond=carfilzomib&draw=2&rank=3."},{"key":"ref_93","unstructured":"(2021, September 20). Phase 1b\/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00531284?term=solid+tumors&cond=carfilzomib."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1113\/EP088762","article-title":"Resistance of Osteosarcoma Cells to the Proapoptotic Effects of Carfilzomib Involves Activation of Mitogen Activated Protein Kinase Pathways","volume":"106","author":"Lei","year":"2021","journal-title":"Exp. Physiol."},{"key":"ref_95","unstructured":"(2021, September 20). Carfilzomib in Combination with Cyclophosphamide and Etoposide for Children-Full Text View-ClinicalTrials.Gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02512926?term=solid+tumors&cond=carfilzomib&draw=2&rank=1."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1111\/bcp.12991","article-title":"Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor, in Solid Tumour Patients with Moderate or Severe Hepatic Impairment","volume":"82","author":"Gupta","year":"2016","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Wilson-Robles, H., Miller, T., Sima, C., and Bittner, M. (2021, September 12). Evaluation of Two Novel Therapeutics against Human and Canine Osteosarcoma. Available online: https:\/\/www.researchsquare.com\/article\/rs-51104\/v1.","DOI":"10.21203\/rs.3.rs-51104\/v1"},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Harris, M.A., Miles, M.A., Shekhar, T.M., Cerra, C., Georgy, S.R., Ryan, S.D., Cannon, C.M., and Hawkins, C.J. (2020). The Proteasome Inhibitor Ixazomib Inhibits the Formation and Growth of Pulmonary and Abdominal Osteosarcoma Metastases in Mice. Cancers, 12.","DOI":"10.3390\/cancers12051207"},{"key":"ref_99","unstructured":"(2021, September 27). Study of Ixazomib and Erlotinib in Solid Tumors-Full Text View-ClinicalTrials.Gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02942095?term=Ixazomib&cond=solid+tumors&draw=1&rank=1."},{"key":"ref_100","unstructured":"(2021, September 27). MLN9708 and Vorinostat in Patients with Advanced P53 Mutant Malignancies-Full Text View-ClinicalTrials.Gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02042989?term=Ixazomib&cond=solid+tumors&draw=1&rank=6."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1038\/s41598-020-58366-z","article-title":"Phase I Studies of Vorinostat with Ixazomib or Pazopanib Imply a Role of Antiangiogenesis-Based Therapy for TP53 Mutant Malignancies","volume":"10","author":"Wang","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_102","first-page":"4752","article-title":"Phase I Study of the Proteasome Inhibitor Bortezomib in Pediatric Patients with Refractory Solid Tumors: A Children\u2019s Oncology Group Study (ADVL0015)","volume":"22","author":"Blaney","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_103","unstructured":"(2022, May 25). Bortezomib With Gemcitabine\/Doxorubicin in Patients with Urothelial Cancer and Other Solid Tumors-Full Text View-ClinicalTrials.Gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00479128?recrs=d&cond=bortezomib+in+metastatic+tumors&draw=2&rank=2."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.1182\/blood-2007-01-065888","article-title":"Potent Activity of Carfilzomib, a Novel, Irreversible Inhibitor of the Ubiquitin-Proteasome Pathway, against Preclinical Models of Multiple Myeloma","volume":"110","author":"Kuhn","year":"2007","journal-title":"Blood"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.3324\/haematol.2013.089334","article-title":"Integrated Safety Profile of Single-Agent Carfilzomib: Experience from 526 Patients Enrolled in 4 Phase II Clinical Studies","volume":"98","author":"Siegel","year":"2013","journal-title":"Haematologica"},{"key":"ref_106","unstructured":"(2021, September 20). A Study of Extended Carfilzomib Therapy for Patients Previously Enrolled in Carfilzomib Treatment Protocols-Study Results -ClinicalTrials.Gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT00884312?term=solid+tumors&cond=carfilzomib&draw=2&rank=4."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","article-title":"Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma","volume":"374","author":"Moreau","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1158\/0008-5472.CAN-09-2766","article-title":"Evaluation of the Proteasome Inhibitor MLN9708 in Preclinical Models of Human Cancer","volume":"70","author":"Kupperman","year":"2010","journal-title":"Cancer Res."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1002\/jcph.719","article-title":"The Effect of a High-Fat Meal on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor, in Patients with Advanced Solid Tumors or Lymphoma","volume":"56","author":"Gupta","year":"2016","journal-title":"J. Clin. Pharmacol."},{"key":"ref_110","unstructured":"(2021, September 20). Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed\/Refractory Multiple Myeloma and Advanced Solid Tumors Participants with Normal Renal Function or Severe Renal Impairment-Full Text View-ClinicalTrials.Gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01830816."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s10637-017-0509-1","article-title":"A Phase I Study to Assess the Mass Balance, Excretion, and Pharmacokinetics of [14C]-Ixazomib, an Oral Proteasome Inhibitor, in Patients with Advanced Solid Tumors","volume":"36","author":"Gupta","year":"2018","journal-title":"Investig. New Drugs"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/bs.acr.2015.03.002","article-title":"Emerging Therapeutic Strategies for Overcoming Proteasome Inhibitor Resistance","volume":"127","author":"Dolloff","year":"2015","journal-title":"Adv. Cancer Res."},{"key":"ref_113","unstructured":"(2021, September 27). Phase 1 Study of Oprozomib Administered Orally in Patients with Advanced Refractory or Recurrent Solid Tumors-Full Text View-ClinicalTrials.Gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01129349?term=solid+tumors&cond=oprozomib&draw=2&rank=1."},{"key":"ref_114","unstructured":"(2021, September 27). Phase I Study of the Proteosome Inhibitor CEP 18770 in Patients with Solid Tumours or Non-Hodgkin\u2019s Lymphomas-Full Text View-ClinicalTrials.Gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00572637?term=solid+tumors&cond=delanzomib&draw=2&rank=1."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1177\/09603271211017972","article-title":"Proteasome Inhibitor MG132 Induces Apoptosis in Human Osteosarcoma U2OS Cells","volume":"40","author":"Lee","year":"2021","journal-title":"Hum. Exp. Toxicol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/j.cellbi.2007.03.037","article-title":"Caspase-8 Dependent Osteosarcoma Cell Apoptosis Induced by Proteasome Inhibitor MG132","volume":"31","author":"Yan","year":"2007","journal-title":"Cell Biol. Int."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1615\/CritRevOncog.2015013713","article-title":"Osteosarcoma Genetics and Epigenetics: Emerging Biology and Candidate Therapies","volume":"20","author":"Morrow","year":"2015","journal-title":"Crit. Rev. Oncog."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"3458","DOI":"10.1038\/s41388-019-0675-z","article-title":"Proteasome Inhibition Boosts Autophagic Degradation of Ubiquitinated-AGR2 and Enhances the Antitumor Efficiency of Bevacizumab","volume":"38","author":"Wang","year":"2019","journal-title":"Oncogene"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"796","DOI":"10.3892\/mmr.2015.4599","article-title":"Induction of Autophagy by the MG-132 Proteasome Inhibitor Is Associated with Endoplasmic Reticulum Stress in MCF-7 Cells","volume":"13","author":"Bao","year":"2016","journal-title":"Mol. Med. Rep."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/s41419-022-04741-9","article-title":"Cisplatin Resistance Can Be Curtailed by Blunting Bnip3-Mediated Mitochondrial Autophagy","volume":"13","author":"Vianello","year":"2022","journal-title":"Cell Death Dis."},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Schott, C.R., Ludwig, L., Mutsaers, A.J., Foster, R.A., and Wood, G.A. (2018). The Autophagy Inhibitor Spautin-1, Either Alone or Combined with Doxorubicin, Decreases Cell Survival and Colony Formation in Canine Appendicular Osteosarcoma Cells. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0206427"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"127508","DOI":"10.1016\/j.bmcl.2020.127508","article-title":"Design, Synthesis and Biological Evaluation of Triaryl Compounds as Novel 20S Proteasome Inhibitors","volume":"30","author":"Yang","year":"2020","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jconrel.2015.05.286","article-title":"Tumor Vascular Targeted Liposomal-Bortezomib Minimizes Side Effects and Increases Therapeutic Activity in Human Neuroblastoma","volume":"211","author":"Zuccari","year":"2015","journal-title":"J. Control. Release"},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Zhang, X., Linder, S., and Bazzaro, M. (2020). Drug Development Targeting the Ubiquitin\u2013Proteasome System (UPS) for the Treatment of Human Cancers. Cancers, 12.","DOI":"10.3390\/cancers12040902"},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Lai, K.P., Chen, J., and Tse, W.K.F. (2020). Role of Deubiquitinases in Human Cancers: Potential Targeted Therapy. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21072548"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.canlet.2019.10.015","article-title":"Targeting USP9x\/SOX2 Axis Contributes to the Anti-Osteosarcoma Effect of Neogambogic Acid","volume":"469","author":"Chen","year":"2020","journal-title":"Cancer Lett."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.3892\/ijo.2016.3752","article-title":"Gene Silencing of USP1 by Lentivirus Effectively Inhibits Proliferation and Invasion of Human Osteosarcoma Cells","volume":"49","author":"Liu","year":"2016","journal-title":"Int. J. Oncol."},{"key":"ref_128","first-page":"6947","article-title":"MicroRNA-192-5p Suppresses the Initiation and Progression of Osteosarcoma by Targeting USP1","volume":"15","author":"Zhou","year":"2018","journal-title":"Oncol. Lett."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1010428317717138","article-title":"USP17 Is Upregulated in Osteosarcoma and Promotes Cell Proliferation, Metastasis, and Epithelial\u2013Mesenchymal Transition through Stabilizing SMAD4","volume":"39","author":"Song","year":"2017","journal-title":"Tumor Biol."},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Luu, A.K., Cadieux, M., Wong, M., Macdonald, R., Jones, R., Choi, D., Oblak, M., Brisson, B., Sauer, S., and Chafitz, J. (2022). Proteomic Assessment of Extracellular Vesicles from Canine Tissue Explants as a Pipeline to Identify Molecular Targets in Osteosarcoma: PSMD14\/Rpn11 as a Proof of Principle. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23063256"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.2217\/fon.14.30","article-title":"Efficacy of Therapy with Bortezomib in Solid Tumors: A Review Based on 32 Clinical Trials","volume":"10","author":"Huang","year":"2014","journal-title":"Future Oncol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1158\/0008-5472.CAN-06-2258","article-title":"Extensive Immunoglobulin Production Sensitizes Myeloma Cells for Proteasome Inhibition","volume":"67","author":"Meister","year":"2007","journal-title":"Cancer Res."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ccr.2007.07.004","article-title":"Frequent Engagement of the Classical and Alternative NF-\u039aB Pathways by Diverse Genetic Abnormalities in Multiple Myeloma","volume":"12","author":"Annunziata","year":"2007","journal-title":"Cancer Cell"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ccr.2007.07.003","article-title":"Promiscuous Mutations Activate the Noncanonical NF-\u039aB Pathway in Multiple Myeloma","volume":"12","author":"Keats","year":"2007","journal-title":"Cancer Cell"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.7150\/jca.52414","article-title":"Proteasome Complexes and Their Heterogeneity in Colorectal, Breast and Pancreatic Cancers","volume":"12","author":"Zagirova","year":"2021","journal-title":"J. Cancer"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/gcc.10291","article-title":"Frequent Amplification and Rearrangement of Chromosomal Bands 6p12-P21 and 17p11.2 in Osteosarcoma","volume":"39","author":"Lau","year":"2004","journal-title":"Genes Chromosomes Cancer"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S0165-4608(96)00306-8","article-title":"Cytogenetic Findings in 73 Osteosarcoma Specimens and a Review of the Literature","volume":"95","author":"Bridge","year":"1997","journal-title":"Cancer Genet. Cytogenet."},{"key":"ref_138","doi-asserted-by":"crossref","unstructured":"Muff, R., Rath, P., Kumar, R.M.R., Husmann, K., Born, W., Baudis, M., and Fuchs, B. (2015). Genomic Instability of Osteosarcoma Cell Lines in Culture: Impact on the Prediction of Metastasis Relevant Genes. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0125611"},{"key":"ref_139","doi-asserted-by":"crossref","unstructured":"Maeda, J., Yurkon, C.R., Fujisawa, H., Kaneko, M., Genet, S.C., Roybal, E.J., Rota, G.W., Saffer, E.R., Rose, B.J., and Hanneman, W.H. (2012). Genomic Instability and Telomere Fusion of Canine Osteosarcoma Cells. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0043355"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1126\/science.1142210","article-title":"Effects of Aneuploidy on Cellular Physiology and Cell Division in Haploid Yeast","volume":"317","author":"Torres","year":"2007","journal-title":"Science"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1101\/gad.207407.112","article-title":"Aneuploidy Causes Proteotoxic Stress in Yeast","volume":"26","author":"Oromendia","year":"2012","journal-title":"Genes Dev."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1354\/vp.39-3-372","article-title":"Tumor Suppressor PTEN Is Mutated in Canine Osteosarcoma Cell Lines and Tumors","volume":"39","author":"Levine","year":"2002","journal-title":"Vet. Pathol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/ng.3293","article-title":"A Sleeping Beauty Forward Genetic Screen Identifies New Genes and Pathways Driving Osteosarcoma Development and Metastasis","volume":"47","author":"Moriarity","year":"2015","journal-title":"Nat. Genet."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1002\/cncr.23782","article-title":"Copy number gains in egfr and copy number losses in pten are common events in osteosarcoma tumors","volume":"113","author":"Freeman","year":"2008","journal-title":"Cancer"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/nrc3838","article-title":"Translational Biology of Osteosarcoma","volume":"14","author":"Kansara","year":"2014","journal-title":"Nat. Rev. Cancer."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"eaay0152","DOI":"10.1126\/scitranslmed.aay0152","article-title":"PTEN Status Determines Chemosensitivity to Proteasome Inhibition in Cholangiocarcinoma","volume":"12","author":"Jiang","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/nrc1505","article-title":"The Role of the Unfolded Protein Response in Tumor Development: Friend or Foe?","volume":"4","author":"Ma","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"ref_148","doi-asserted-by":"crossref","unstructured":"Siwecka, N., Rozp\u0119dek, W., Pytel, D., Wawrzynkiewicz, A., Dziki, A., Dziki, \u0141., Diehl, J.A., and Majsterek, I. (2019). Dual Role of Endoplasmic Reticulum Stress-Mediated Unfolded Protein Response Signaling Pathway in Carcinogenesis. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20184354"},{"key":"ref_149","first-page":"1704","article-title":"Protein Profiling of Osteosarcoma Tissue and Soft Callus Unveils Activation of the Unfolded Protein Response Pathway","volume":"54","author":"Chaiyawat","year":"2019","journal-title":"Int. J. Oncol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.neo.2016.09.001","article-title":"Upregulation of Glucose-Regulated Protein 78 in Metastatic Cancer Cells Is Necessary for Lung Metastasis Progression","volume":"18","author":"Lizardo","year":"2016","journal-title":"Neoplasia"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.neo.2019.02.004","article-title":"ATF6\u03b1 Activation Enhances Survival against Chemotherapy and Serves as a Prognostic Indicator in Osteosarcoma","volume":"21","author":"Yarapureddy","year":"2019","journal-title":"Neoplasia"},{"key":"ref_152","first-page":"10204","article-title":"Activation of Unfolded Protein Response Protects Osteosarcoma Cells from Cisplatin-Induced Apoptosis through NF-\u039aB Pathway","volume":"8","author":"Yan","year":"2015","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.canlet.2017.09.021","article-title":"GRP78 Inhibition Enhances ATF4-Induced Cell Death by the Deubiquitination and Stabilization of CHOP in Human Osteosarcoma","volume":"410","author":"Luo","year":"2017","journal-title":"Cancer Lett."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"4250","DOI":"10.2174\/092986711797189574","article-title":"Targeting Heat Shock Proteins 70\/90 and Proteasome for Cancer Therapy","volume":"18","author":"Wang","year":"2011","journal-title":"Curr. Med. Chem."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s44164-022-00008-x","article-title":"Osteosarcoma Tumor Microenvironment: The Key for the Successful Development of Biologically Relevant 3D in Vitro Models","volume":"1","author":"Rodrigues","year":"2022","journal-title":"In Vitro Models"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-021-98450-6","article-title":"Proteasome Inhibition by Bortezomib Parallels a Reduction in Head and Neck Cancer Cells Growth, and an Increase in Tumor-Infiltrating Immune Cells","volume":"11","author":"Benvenuto","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/s41416-020-01191-y","article-title":"Modulating Proteasome Inhibitor Tolerance in Multiple Myeloma: An Alternative Strategy to Reverse Inevitable Resistance","volume":"124","author":"Ge","year":"2020","journal-title":"Br. J. Cancer"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/19\/4544\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:34:50Z","timestamp":1760142890000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/19\/4544"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,20]]},"references-count":157,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["cancers14194544"],"URL":"https:\/\/doi.org\/10.3390\/cancers14194544","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,20]]}}}